Compare SCOR & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | NRSN |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | Israel |
| Employees | N/A | 15 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 28.4M |
| IPO Year | 2007 | N/A |
| Metric | SCOR | NRSN |
|---|---|---|
| Price | $7.08 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 15.1K | ★ 153.2K |
| Earning Date | 03-17-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,549,000.00 | N/A |
| Revenue This Year | $2.01 | N/A |
| Revenue Next Year | $1.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $4.39 | $0.68 |
| 52 Week High | $10.18 | $2.60 |
| Indicator | SCOR | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 39.05 |
| Support Level | $7.09 | $0.68 |
| Resistance Level | $8.27 | $1.30 |
| Average True Range (ATR) | 0.57 | 0.07 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 58.34 | 11.94 |
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.